5990725
Last Update Posted: 2025-04-24
Recruiting has ended
All Genders accepted | 12 Years + |
240 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Eligibility
Relevant conditions:
Atopic Dermatitis
Eczema
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov